Intracerebral Haemorrhage – From Blood Pressure Control to Secondary Brain Injury

In this episode of Voice of Stroke we explore major recent advances in intracerebral haemorrhage research.

This episode discusses:

• The TRIDENT trial and long-term blood pressure lowering after ICH
• Perihaematomal oedema growth as a biomarker of secondary brain injury
• Translational neuroimmunology and inflammatory signalling after haemorrhage
• Highlights from the ESO ICH Academy Meeting in Maastricht

Featuring discussion of recent publications in the New England Journal of Medicine, Stroke, and Annals of Neurology.

Written by Voice of Stroke Podcast Editor-in-Chief Linxin Li and Co-editor Annemijn Algra.

Listen on Spotify, Apple Podcasts, and via the European Stroke Organisation website.

Read the full transcript here.

References

1. The Trident Research Group. Three Low-Dose Antihypertensive Agents in a Single Pill after Intracerebral Hemorrhage. N Engl J Med. 2026; 394: 1571-1582. doi: 10.1056/NEJMoa2515043. https://www.nejm.org/doi/full/10.1056/NEJMoa2515043

2. Samarasekera N et al. Perihematomal Edema and Functional Outcome After Intracerebral Hemorrhage: A Meta-Analysis of Individual Participant Data. Stroke 2026; 57: 1310-1324. doi: 10.1161/STROKEAHA.125.053991. https://www.ahajournals.org/doi/epdf/10.1161/STROKEAHA.125.053991

3. Parry-Jones A et al. Hematoma Interleukin-1 ReceptorAntagonist Concentrations PredictLong-Term Outcome in AcuteHuman Intracerebral Hemorrhage. Ann Neurol 2026; 00: 1-16. doi: 10.1002/ana.78237. https://onlinelibrary.wiley.com/doi/epdf/10.1002/ana.78237

4. ICH Academy Meeting: https://eso-stroke.org/resources/eso-ich-academy-meeting-iam/